Glucagon-like peptide-1 (GLP-1) receptor agonists, widely prescribed for type 2 diabetes and weight management, are known for their metabolic benefits but may have unrecognized side effects. This study investigates the association between GLP-1 receptor agonists and male sexual dysfunction using data from the FDA Adverse Event Reporting System (FAERS). Reports from Q4 2003 to Q1 2024 were analyzed using the OpenVigil 2.1 platform to identify male patients experiencing orgasmic dysfunction, erectile dysfunction, or decreased libido linked to GLP-1 receptor agonists (tirzepatide, semaglutide, dulaglutide, exenatide, lixisenatide, and liraglutide). After cleaning duplicate entries, disproportionality measures (reporting odds ratio (ROR), proportional reporting ratio (PRR), and relative reporting ratio (RRR)) were calculated, with Evans' criteria applied to assess signal significance. Among 182 cases identified, patients were predominantly aged 40-60 years, with exenatide accounting for 24.2% of reports, followed by semaglutide (21.4%). Diabetes was the most common indication (43.9%). Despite statistically significant chi-squared values (P < 0.0001), low ROR (0.41, 95% Confidence interval (CI): 0.36-0.48), PRR (0.41, 95% CI: 0.36-0.48), and RRR (0.42, 95% CI: 0.36-0.48) suggest a weak association. These findings underscore the need for monitoring as GLP-1 use expands, though overall patient risk remains low.
International journal of impotence research. 2025 Apr 16 [Epub ahead of print]
Ashkan Pourabhari Langroudi, Abby L Chen, Satvir Basran, Elijah R Sommer, James Stinson, Yu-Sheng Cheng, Francesco Del Giuduce, Michael Scott, Michael L Eisenberg
Department of Urology, School of Medicine, Stanford University, Stanford, CA, USA., Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy., Department of Urology, School of Medicine, Stanford University, Stanford, CA, USA. .